# JAKAFI XR

NDC: 50881-044
Generic name: ruxolitinib
Labeler / Manufacturer: Incyte Corporation
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: TABLET, EXTENDED RELEASE
Routes: ORAL
Marketing started: 20260501

FDA application: NDA217180

## Active ingredients

- RUXOLITINIB: 44 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"50881-044"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=50881-044
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b